Intelligent Bio Solutions Secures Eighth European Patent for Drug Testing Tech
Event summary
- Intelligent Bio Solutions received European Patent EP3752831 on March 26, 2026, for contextualizing fingerprint chemical analysis with deposition volume.
- This is the company's eighth European patent, strengthening its IP portfolio around fingerprint sweat drug testing technology.
- The patent protects advancements in correlating chemical findings with fingerprint residue volume, improving test interpretation.
- Intelligent Bio Solutions' European IP portfolio now covers multiple aspects of its screening system, including sample collection and test strip readers.
The big picture
Intelligent Bio Solutions' latest patent grant underscores its commitment to advancing non-invasive drug testing technology. The company's growing European IP portfolio positions it as a formidable competitor in the medical technology sector, particularly in safety-critical industries. This strategic move aligns with broader industry trends toward faster, more dignified testing methods that address logistical and privacy concerns associated with traditional sample collection.
What we're watching
- IP Strategy
- How Intelligent Bio Solutions will leverage this expanded European IP portfolio to strengthen its market position against traditional drug screening methods.
- Technological Advancement
- Whether the company can sustain its pace of innovation in fingerprint sweat analysis to maintain competitive edge.
- Market Expansion
- The pace at which Intelligent Bio Solutions can penetrate safety-critical sectors in Europe with its non-invasive testing solutions.